Withdrawal effects sits at the center of this dementia and brain health question.
Stopping dementia medications — particularly the cholinesterase inhibitors donepezil (Aricept), rivastigmine, and galantamine — can trigger a significant and sometimes rapid decline in both cognitive function and behavior. When discontinued abruptly, these drugs can cause what is known as cholinergic rebound: a central nervous system reaction that produces nausea, insomnia, tremors, agitation, aggression, and even hallucinations. For the second major class of dementia medication, memantine (Namenda), abrupt cessation has been linked to behavioral disturbances including increased agitation and anxiety. In short, the withdrawal effects are real, clinically meaningful, and in many cases preventable with a carefully managed taper.
Consider a family whose mother with moderate Alzheimer’s is hospitalized for a hip fracture. In the chaos of the hospital stay, her donepezil is quietly discontinued. Within weeks, the family notices she seems more confused than before the surgery, less able to recognize familiar faces, and agitated in ways she wasn’t previously. This scenario plays out regularly and illustrates why the decision to stop dementia medications deserves the same clinical deliberation as the decision to start them. This article covers what happens physiologically when these drugs are stopped, which patients face the greatest risk, how to taper safely, and when discontinuation may actually be appropriate.
Table of Contents
- What Are the Withdrawal Effects of Stopping Dementia Medications?
- How Quickly Does Cognitive Decline Happen After Stopping Dementia Drugs?
- Cholinergic Rebound — The Physical Side Effects of Stopping Aricept and Related Drugs
- How to Safely Stop Dementia Medications — Tapering Protocols
- When Is It Actually Appropriate to Stop Dementia Medications?
- The Broader Problem — Inappropriate Prescribing in Older Adults with Dementia
- The Future of Dementia Treatment and What It Means for Stopping Older Medications
- Conclusion
- Frequently Asked Questions
What Are the Withdrawal Effects of Stopping Dementia Medications?
The most clinically significant withdrawal effect of stopping cholinesterase inhibitors is a phenomenon called cholinergic rebound. These medications work by blocking the enzyme that breaks down acetylcholine, a neurotransmitter critical for memory and attention. When the drug is removed suddenly, the brain’s acetylcholine system is thrown into imbalance, and the central nervous system reacts. Symptoms include nausea, vomiting, insomnia, tremors or shaking, and in more severe cases, agitation, aggression, and hallucinations. These effects can appear within days of stopping the medication and may be mistaken for a new psychiatric episode or a sudden worsening of the underlying disease. Beyond the rebound reaction, there is the question of cognitive decline.
A 2021 Cochrane review found low-certainty evidence that discontinuing cholinesterase inhibitors leads to worse cognitive function and greater functional impairment within two months compared to continuing them. Caregivers and patients in observational studies have described this as sudden and dramatic — not a gradual slide but a step-down change that catches families off guard. This is not universal, but the risk is significant enough that most clinicians treat discontinuation as a meaningful clinical event rather than a simple administrative decision. Memantine, which works through a different mechanism targeting the glutamate system, carries a somewhat different withdrawal profile. Stopping it abruptly tends to affect behavior more than cognition, with patients showing increased agitation and anxiety in the days and weeks following cessation. Because memantine is often prescribed alongside a cholinesterase inhibitor in moderate-to-severe Alzheimer’s, stopping both at once compounds the risk considerably.
How Quickly Does Cognitive Decline Happen After Stopping Dementia Drugs?
The timeline for cognitive and functional decline after stopping these medications is compressed in ways many families do not anticipate. The Cochrane evidence suggests meaningful deterioration can occur within the short term — defined in the research as up to two months — when cholinesterase inhibitors are discontinued. Caregivers in one BMC Palliative Care study described the decline as rapid and striking, using language that implied the change happened over days to weeks rather than months. What often gets lost in clinical handoffs is that the drug’s benefits, while modest on a population level, may be masking a level of underlying dysfunction that becomes visible quickly once the medication is gone. It is worth being precise about what “decline” means in this context. Cognitive function — measured by tools like the MMSE or ADAS-Cog — worsens, but so does functional ability: the capacity to perform activities of daily living like dressing, eating, and navigating familiar spaces.
Behavioral symptoms, including sleep disturbances and agitation, are also commonly reported. For a family managing a loved one at home, any one of these changes can dramatically increase the burden of care. However, the evidence for harm is strongest in patients with mild-to-moderate dementia. A 2022 study published in PMC found that in institutionalized patients with advanced dementia, discontinuation of cholinesterase inhibitors was not associated with measurable cognitive, behavioral, or functional deterioration. This is a meaningful caveat. For someone in the late stages of the disease, living in a memory care facility, already largely non-verbal and dependent on full care, the net benefit of continuing these medications may be minimal. The risk-benefit calculation shifts substantially as dementia progresses.
Cholinergic Rebound — The Physical Side Effects of Stopping Aricept and Related Drugs
Cholinergic rebound is not widely discussed in the general patient and caregiver literature, but it is a recognized clinical concern documented by pharmacists and clinicians who specialize in this population. When acetylcholinesterase inhibitors are stopped abruptly, the sudden change in cholinergic tone in the central nervous system produces a cluster of symptoms that can be distressing and, in older adults with dementia, potentially destabilizing. Nausea and vomiting are among the more physically uncomfortable effects; insomnia compounds the disorientation and agitation that can follow. The neuropsychiatric symptoms are often the most alarming for families.
Agitation, aggression, and hallucinations following abrupt cessation can lead to emergency room visits and, in some cases, the inappropriate initiation of antipsychotic medications — drugs that carry their own serious risks in elderly patients with dementia. In this way, stopping one medication abruptly can set off a clinical cascade that results in more medications, not fewer. A practical example: a patient on donepezil 10mg who is abruptly taken off the medication after a hospitalization may, within a week, become combative during personal care, stop sleeping through the night, and begin seeing things that aren’t there. A family unfamiliar with cholinergic rebound will reasonably assume the dementia has progressed rapidly — and may not realize that a slow, supervised taper could have prevented most or all of these symptoms.
How to Safely Stop Dementia Medications — Tapering Protocols
Gradual tapering is universally recommended over abrupt cessation when the decision to stop a dementia medication has been made. Clinicians typically reduce the dose every four weeks, often by 50% at each step. For donepezil, this might mean moving from 10mg to 5mg for four weeks before stopping entirely. For rivastigmine patch formulations, it means stepping down through available patch doses on a similar schedule. This approach gives the brain time to re-equilibrate and significantly reduces the risk of cholinergic rebound and behavioral destabilization. When a patient is on both a cholinesterase inhibitor and memantine, standard practice is to taper one drug at a time — not both simultaneously.
Clinicians generally recommend starting with whichever medication is causing the most noticeable side effects. This approach requires more time and more careful monitoring, but it protects the patient from the compounded withdrawal effects of losing both pharmacological supports at once. The tradeoff is a longer transition period, which requires sustained engagement from both the prescribing physician and the caregiving team. It is also worth noting that the decision to deprescribe is itself a clinical event requiring documentation and follow-up. A 2024 survey of Canadian dementia experts published in ScienceDirect found reasonable consensus that discontinuation is appropriate in three circumstances: patient or caregiver preference, severe adverse events from the medication, or end-of-life care. Outside of these circumstances, the bar for stopping should be high — particularly in patients with mild-to-moderate disease where the evidence of harm from stopping is most robust.
When Is It Actually Appropriate to Stop Dementia Medications?
The question of when to stop is as important as how to stop. End-of-life care is one of the clearest and most widely accepted indications for deprescribing dementia medications. Hospice and palliative care guidelines, including those from the Palliative Care Network of Wisconsin, identify cholinesterase inhibitors as medications commonly deprescribed at end of life to reduce pill burden and minimize side effects. When a person is actively dying or transitioning to comfort-focused care, the modest cognitive benefit of these drugs is outweighed by the burden of swallowing pills, the risk of nausea, and the complexity of the medication regimen. Advanced dementia also presents a reasonable case for reconsideration.
As noted earlier, research in institutionalized patients with severe, late-stage disease found no significant deterioration after stopping cholinesterase inhibitors. When communication has been lost, behavioral and functional baselines are already significantly impaired, and the patient is entirely dependent on care, the rationale for continuing these medications becomes harder to defend on clinical grounds alone. A warning worth emphasizing: the appropriateness of stopping should always be evaluated individually, in conversation with the treating physician. A blanket assumption that “she’s too far gone for it to matter” without clinical assessment is not a safe framework. Dementia staging is imprecise, and two patients with the same diagnosis may have very different trajectories. The decision should involve a geriatrician, neurologist, or palliative care specialist where possible — not be made unilaterally in the context of a hospitalization or a medication reconciliation error.
The Broader Problem — Inappropriate Prescribing in Older Adults with Dementia
The conversation about stopping dementia medications does not exist in isolation. A January 2026 study reported in ScienceDaily found that one in four older adults with dementia is still being prescribed medications linked to falls and confusion — a figure that underscores how common inappropriate or unreviewed prescribing remains in this population. Dementia medications are sometimes continued long past the point of likely benefit, not because of a deliberate clinical decision, but because of inertia in the system and the difficulty of these conversations with families.
This context matters for caregivers navigating the question of whether to stop or continue. The same clinical environment that might fail to taper a medication properly might also fail to flag when continuation no longer makes sense. Advocacy — asking the prescriber directly whether the current medication regimen has been reviewed recently and what the goals of treatment are — is both appropriate and necessary.
The Future of Dementia Treatment and What It Means for Stopping Older Medications
The landscape of dementia treatment is shifting. The Lancet’s 2024 dementia commission report highlights a broader movement toward early intervention and disease-modifying therapies, particularly anti-amyloid drugs that target the underlying pathology of Alzheimer’s disease rather than managing symptoms.
As these newer treatments become more widely available, clinical guidance on when to start and stop older symptomatic medications like donepezil and memantine is likely to evolve. For patients currently on cholinesterase inhibitors or memantine, this shift is mostly future context. But it signals that the field is moving toward a more nuanced and stage-specific approach to pharmacological management of dementia — one in which the question of stopping medications will become more individualized, better informed by disease-modifying goals, and increasingly guided by what matters most to patients and families at each stage of the illness.
Conclusion
Stopping dementia medications — whether abruptly or through a poorly managed taper — carries real risks, particularly for patients in the mild-to-moderate stages of the disease. Cholinergic rebound from abrupt cessation of drugs like donepezil can produce nausea, insomnia, tremors, agitation, and hallucinations. Beyond these acute symptoms, cognitive and functional decline can occur within weeks, as documented in Cochrane review evidence. Memantine withdrawal adds behavioral disturbances to the picture.
The safest approach is a gradual dose reduction over multiple weeks, one drug at a time, under physician supervision. That said, discontinuation is sometimes the right clinical decision — especially at end of life, in advanced dementia, or in response to serious adverse events. The key is that it should be a decision, not an accident. Caregivers who notice a sudden deterioration after a medication change should raise it immediately with the treating physician. And families managing loved ones in later stages of the disease should feel empowered to ask their doctors directly: is there still a clear benefit to continuing these medications, and if not, how do we stop them safely?.
Frequently Asked Questions
How long does it take to see cognitive decline after stopping Aricept (donepezil)?
Evidence from a Cochrane review suggests measurable cognitive and functional decline can occur within two months of stopping cholinesterase inhibitors. Some caregivers report noticing changes within days to weeks, particularly if the medication was stopped abruptly.
Can stopping dementia medication cause hallucinations?
Yes. Abrupt discontinuation of cholinesterase inhibitors can trigger cholinergic rebound, a central nervous system reaction that includes hallucinations, agitation, aggression, tremors, and insomnia. These symptoms can be mistaken for a new psychiatric episode or rapid disease progression.
Is it ever safe to stop dementia medications?
Yes, under the right circumstances. End-of-life care, severe medication side effects, and patient or caregiver preference supported by clinical review are recognized indications for stopping. In patients with advanced dementia, research suggests discontinuation may not worsen outcomes significantly.
Should you stop donepezil and memantine at the same time?
No. Standard practice is to taper one medication at a time, typically starting with the one causing the most side effects. Stopping both simultaneously increases the risk of withdrawal effects and behavioral destabilization.
How should dementia medications be tapered?
Clinicians typically reduce the dose by approximately 50% every four weeks until the medication is stopped entirely. For donepezil, this often means stepping down from 10mg to 5mg before discontinuing. The process should be supervised by a physician.
What should a caregiver do if they notice sudden decline after a medication change?
Contact the prescribing physician immediately. Sudden changes in cognition, behavior, or function following medication discontinuation should be treated as a clinical concern, not simply as disease progression. A reinstatement of the medication or a more careful taper may be warranted.
You Might Also Like
- What are the side effects of donepezil for dementia
- What are the risks of polypharmacy in elderly dementia patients
- What are the risks of benzodiazepines in elderly dementia patients
For more, see Alzheimer’s Association.
